SCHEMBL3015848

SCHEMBL3015848

O=S(=O)(c1c(F)c(F)c(F)c(F)c1F)N1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.39
POLB P06746 1/20 0.38
AR P10275 1/20 0.38
MAPK1 P28482 3/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAPT P10636 5/20 0.37
GBA1 P04062 2/20 0.37
LMNA P02545 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FPR2 P25090 5/20 0.36
PROKR1 Q8TCW9 5/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023374 0.90 PKM (0.45) SMN1; SMN2ALDH1A1L3MBTL1GAAAR
SCHEMBL3013754 0.88 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1L3MBTL1POLBMAPK1
SCHEMBL3000979 0.87 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB
SCHEMBL3003729 0.87 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB
SCHEMBL3002640 0.86 POLB (0.52) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB
SCHEMBL3015282 0.86 TRPV4 (0.46) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB
SCHEMBL3012544 0.86 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB
SCHEMBL3014554 0.86 EPHX2 (0.49) ALDH1A1GAAPOLBMAPK1NPC1
SCHEMBL3004091 0.86 MEN1 (0.43) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB
SCHEMBL3004828 0.85 POLB (0.44) SMN1; SMN2ALDH1A1L3MBTL1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.